Creative Medical Technology Holdings (CELZ) Net Cash Flow (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Net Cash Flow of -$1.5 million for Q1 2026, down 184.25% year-over-year from $1.8 million in Q1 2025, and down 181.03% quarter-over-quarter from $1.8 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Net Cash Flow (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Net Cash Flow for 17 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 184.25% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$2.0 million (down 51.75% YoY), while the FY2025 annual figure was $1.3 million, down 48.75% from the prior year.
- Net Cash Flow slipped to -$1.5 million in Q1 2026 per CELZ's latest filing, from $1.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $13.7 million in Q2 2022 and bottomed at -$8.6 million in Q4 2022.
- Historically, Net Cash Flow has averaged -$294158.5 across 5 years, with a median of -$1.2 million in 2025.
- On a YoY basis, Net Cash Flow climbed as much as 11869.33% in 2022 and fell as far as 990.29% in 2022.
- Creative Medical Technology Holdings' Net Cash Flow stood at -$8.6 million in 2022, then soared by 87.97% to -$1.0 million in 2023, then jumped by 69.23% to -$320036.0 in 2024, then soared by 672.63% to $1.8 million in 2025, then tumbled by 181.03% to -$1.5 million in 2026.
- Business Quant data shows CELZ's Net Cash Flow at -$1.5 million in Q1 2026, $1.8 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | 2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.99 Mn |
| Jun 30, 2026 | 2.99 Mn |
| Mar 31, 2026 | -1.48 Mn |
| Mar 31, 2026 | -1.48 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | -320,036.00 |
| Dec 31, 2024 | -320,036.00 |
| Sep 30, 2024 | -1.21 Mn |
| Sep 30, 2024 | -1.21 Mn |
| Jun 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | -1.54 Mn |
| Mar 31, 2024 | 5.54 Mn |
| Mar 31, 2024 | 5.54 Mn |